secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001104659-26-001953
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M
--------------------------------------------------------------------------------

- Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.
- Adjusted EBITDA guidance $455-475M, flat versus raised 2025 midpoint.
- Closed $980M syndicated credit facility; repaid $581M Pharmakon term loan, expects annualized interest savings.
- Signed supply/quality agreements with Hikma for authorized generics of Nucynta/Nucynta ER; AG Nucynta ER launch expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/0001104659-26-001953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/tm262493d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer